Sold-out Yorkton conference highlights growing demand for mental health support - MBC Radio

Photo courtesy of The Invincible Brain website Dr. Majid Fotuhi, neurologist and author of The Invincible Brain. Andrea Moss Local Journalism Initiative Reporter SaskToday.ca Mental health challenges that intensified during and after the COVID-19 pandemic continue to drive demand for support, resources and education, according to organizers of a sold-out conference in Yorkton this week. More than 200 people attended the Wellness for Life Mental Health Conference hosted by SaskAbilities on Oct. 7 at the Gallagher Centre’s National Bank Convention Place. Regional director Aleks Hoeber said the annual event was launched after SaskAbilities noticed a growing number of people struggling with their mental health. “We decided to host it shortly after COVID when we noted there was such an increase in individuals struggling with their mental health,” Hoeber said. “People spoke about increased anxieties, significant depression, loneliness and low motivation levels.” Those concerns were being heard from staff, community members and the people SaskAbilities supports, she said.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.